Subunit Vaccine Market Growth Driven by Rising Infectious Disease Burden and Advancements in Genetic Engineering
Subunit vaccine market is driven by the increasing prevalence of infectious diseases, growing demand for safer and more effective immunization solutions, and continuous advancements in biotechnology and genetic engineering. The rising adoption of protein antigen-based and polysaccharide antigen-based vaccines is significantly supporting market growth across multiple disease segments including DTP, HPV, MMR, and other infectious diseases. In addition, increasing government immunization programs, expanding R&D activities in recombinant vaccine development, and growing focus on cell-mediated and mucosal immune responses are further accelerating the expansion of the subunit vaccine market globally. The use of advanced production techniques such as protein denaturation and genetic engineering is also improving vaccine safety, stability, and effectiveness.
Browse the full report description of “Subunit Vaccine Market Size, Share & Trends Analysis Report by Product Type (Protein Antigen, and Polysaccharide Antigen), by Production Type (Denaturing of Proteins, and Genetic Engineering), by Immune Responses Type (Antigen-Presenting Cells (APCs), Cell-Mediated Immunity, Cytokines, Mucosal, and Others), and by Disease (Infectious Disease, Diphtheria, Tetanus and Pertussis (DTP), HPV, Measles, Mumps and Rubella (MMR), and Others)” at https://www.omrglobal.com/industry-reports/subunit-vaccine-market
Expansion of protein-based vaccine commercialization partnerships is expected to drive growth in the subunit vaccine market in 2025–2026
The subunit vaccine market is expected to witness strong growth in 2025–2026 due to increasing commercialization partnerships and global distribution expansions of protein-based vaccine platforms. Rising focus on safer, more targeted, and well-tolerated vaccine technologies is encouraging pharmaceutical companies to expand subunit vaccine portfolios across infectious disease segments. Growing demand for scalable vaccine production and improved global immunization coverage is further supporting adoption of recombinant protein-based vaccine platforms. In 2025–2026, Novavax expanded commercialization of its protein-based subunit vaccine Nuvaxovid through global collaboration with Sanofi, including market expansion in Europe and the United States with scaled distribution networks and revenue-sharing arrangements. This partnership is expected to strengthen global vaccine accessibility while supporting long-term revenue growth in the protein subunit vaccine segment. Additionally, increasing adoption of recombinant vaccine technologies and strategic licensing agreements is anticipated to further accelerate market expansion.
Strategic acquisitions in recombinant subunit vaccine technologies are expected to strengthen hepatitis B vaccine pipelines in 2025–2026
The recombinant subunit vaccine market is expected to experience increasing consolidation in 2025–2026 as major pharmaceutical companies focus on expanding their infectious disease vaccine portfolios through acquisitions and pipeline integration. Rising prevalence of hepatitis B and growing emphasis on preventive healthcare are driving demand for advanced recombinant vaccine technologies with improved immunogenicity and safety profiles. In 2025–2026, Sanofi completed a major acquisition of Dynavax Technologies in a deal valued at approximately $2.2 billion, which includes access to HEPLISAV-B, a recombinant subunit hepatitis B vaccine, along with future vaccine pipeline assets. The acquisition is expected to strengthen Sanofi’s position in the global vaccine market and expand its presence in recombinant subunit vaccine technologies. Furthermore, increasing investment in next-generation vaccine platforms, combined with rising demand for effective long-term immunization solutions, is expected to further support growth in the subunit vaccine segment during the forecast period.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404